Authorized distributor • Original products from Korea • Support in Polish, Russian, English, German and Czech
PL RU EN DE CZ
0
← All products
METABION TirzaFit Pen 40 mg / 3 ml
Metabion

METABION TirzaFit Pen 40 mg / 3 ml

TirzaFit disposable pre-filled pen 40 mg / 3 ml (Tirzepatide INN)

For order — message us on Telegram
Message on Telegram (@obotax_shop)

In stock — dispatch within 48h

❄️ Temperature-controlled delivery (2–8°C) across the EU.

GLP-1 / GIP Dual Agonist Once-Weekly Subcutaneous Pharmaceutical Grade

Overview

METABION TirzaFit 40 mg / 3 mL (purple edition) is a pre-filled multi-dose disposable pen delivering 13.33 mg/ml Tirzepatide INN. Tailored for patients initiating therapy, it provides exceptionally smooth dosing for the standard 2.5 mg and 5.0 mg titration protocols.

Strictly for certified healthcare practitioners and clinical facilities

Dual Incretin Mechanism: GLP-1 + GIP Agonism

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By simultaneously activating both incretin pathways, it exerts synergistic metabolic control: promoting glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, slowing gastric motility, and stimulating central hypothalamic satiety circuits to curb appetite and enhance peripheral insulin sensitivity.

Dual Incretin Mechanism of Action (GLP-1 & GIP Synergy)
Dual Incretin Mechanism of Action • Synergistic GLP-1 & GIP receptor activation across brain, pancreas, stomach, and adipose tissue.

Administration

TirzaFit 40 mg pen. Subcutaneous administration once weekly according to clinical titration schedule.

METABION TirzaFit Pen 40 mg / 3 ml
Pre-filled multi-dose disposable pen anatomy, dial mechanism, and 90° subcutaneous injection technique.

Clinical Dose Titration & Escalation Protocol

To ensure gastrointestinal tolerability, Tirzepatide administration must follow a stepwise escalation protocol. Treatment initiates at a low starting dose of 2.5 mg subcutaneously once weekly for the initial 4 weeks (adaptation phase). The dose is then increased to 5.0 mg once weekly. Subsequent increments of 2.5 mg may occur at minimum 4-week intervals based on clinical assessment and tolerance, up to the maximum dose of 15.0 mg weekly.

Clinical Titration and Escalation Schedule
Standard Once-Weekly Subcutaneous Escalation Schedule • Minimum 4-week adaptation periods between dose tiers.

Technical & Pharmaceutical Specifications

METABION TirzaFit Pen 40 mg / 3 ml Specifications
Active ingredient Tirzepatide INN
Strength & Volume 40 mg in 3 mL (13.33 mg/mL)
Excipients Disodium phosphate, NaCl, HCl, WFI
Device Pre-filled disposable pen
Brand Metabion
Storage 2°C to 8°C

Storage Requirements & Cold Chain Management

Store refrigerated at 2°C to 8°C (36°F to 46°F). Protect from direct light. Do not freeze. For pre-filled pens: once in use, the pen may be kept at room temperature (below 30°C / 86°F) for up to 21-28 days. For reconstituted vials: maintain in refrigerator at 2°C to 8°C and use sterile single-use syringes.

FAQ

How often is the medication administered?

Tirzepatide is injected subcutaneously exactly once per week, at any time of day, with or without meals.